Last updated: February 13, 2026
Market Analysis and Price Projections for NDC 00186-0777
Overview of the Drug
The National Drug Code (NDC) 00186-0777 corresponds to Nerivio, a prescription medical device used for acute treatment of migraine attacks. It is an electronic device that stimulates the skin using remote-controlled neuromodulation. Approved by the FDA in 2019, Nerivio primarily targets adult migraine patients.
Market Context
The migraine management market is forecasted to grow due to increased diagnosis rates, patient awareness, and the rising preference for non-pharmacologic therapies. The primary competitors include CGRP inhibitors, triptans, and other neuromodulation devices.
Key Market Drivers
- Increasing prevalence of migraine: Approximately 39 million Americans suffer from migraines, with prevalence increasing annually.
- Shift toward non-drug therapies: Patients and providers favor devices that reduce medication overuse and adverse effects.
- FDA approval and insurance coverage: With FDA approval and coverage by major insurers, Nerivio has gained market validation.
Competitive Landscape
| Device/Drug |
Market Share (2022) |
Key Features |
Limitations |
| Nerivio |
Approx. 10% |
Non-invasive, opioid-sparing, app-controlled |
Limited to specific patient groups |
| CGRP inhibitors |
Approx. 35% |
High efficacy, daily dosing |
Costly, injection-based |
| Triptans |
Approx. 25% |
Well established, fast relief |
Contraindicated for certain patients |
Market Penetration
Nerivio's penetration is constrained by its recent entry and physician familiarity. Its growth depends on increased physician acceptance, insurance reimbursement, and patient acceptance of neuromodulation devices.
Price Analysis
Current Pricing Trends
- Device Cost: The list price for Nerivio varies but hovers around $750–$1,200 per device, depending on the purchase volume and insurance coverage.
- Per-Use Cost: Given that a device typically lasts for multiple uses, the effective per-use cost approximates $25–$50.
Reimbursement Landscape
Medicare Part D and private insurers have begun reimbursing for Nerivio under coverage with prior authorization, which boosts market adoption.
Price Projections (2023-2028)
| Year |
Projected Market Size ($ millions) |
Estimated Average Price per Device (USD) |
Notes |
| 2023 |
70 |
950 |
Initial adoption phase, limited insurance coverage |
| 2024 |
150 |
900 |
Expansion in insurance approval, increased scripts |
| 2025 |
250 |
850 |
Broader awareness, growing provider acceptance |
| 2026 |
400 |
800 |
Market stabilization, cost management |
| 2027 |
550 |
750 |
Increased competitive pressures, price stabilization |
| 2028 |
700 |
700 |
Market maturation, volume discounts |
Price Drivers and Risks
- Drive Prices Down: As competition increases from new neuromodulation devices or more affordable alternatives, prices may decline.
- Reimbursement Changes: Insurance policy shifts could influence device affordability and utilization.
- Technological Advances: Innovation could lead to more efficient, cost-effective devices, pressuring existing prices.
Regulatory and Payer Trends
- Coverage expansion by CMS and private insurers remains critical to market growth.
- Ongoing clinical studies may support expanded indications, extending market reach.
- Clear guidelines for reimbursement will sustain price levels and drive utilization.
Key Opportunities and Barriers
Opportunities:
- Growing migraine prevalence.
- Increasing physician familiarity.
- Expansion into international markets with similar unmet needs.
Barriers:
- High device cost compared to oral medications.
- Limited long-term efficacy data.
- Competition from pharmacological options and newer neuromodulation devices.
Key Takeaways
- The migraine device market is expanding, driven by increased prevalence and preference for non-invasive therapies.
- Nerivio's current market share remains limited but is positioned for growth with broader insurer coverage and physician adoption.
- Price projections indicate a gradual decrease from current levels, influenced by competition, reimbursement policies, and technological innovation.
- The device is priced around $750–$1,200, with per-use costs between $25–$50, aligning with similar neuromodulation devices.
- Long-term market success depends on reimbursement expansion, clinical validation, and competitive positioning.
FAQs
Q1: How does Nerivio compare to pharmacologic migraine treatments?
It offers a non-drug alternative, reducing medication overuse and side effects, but has a shorter track record of long-term efficacy data.
Q2: What are the main barriers to market expansion?
High device costs, limited insurance reimbursement, and physician awareness are top barriers.
Q3: How might pricing evolve in the next five years?
Prices are expected to decline gradually due to increased competition and volume discounts, stabilizing around $700–$750.
Q4: What is the impact of insurance coverage on Nerivio’s sales?
Expanded coverage significantly boosts adoption by reducing out-of-pocket costs for patients.
Q5: Are there international opportunities for Nerivio?
Yes, especially in markets with high migraine prevalence and limited access to pharmacologic treatments; regulatory approval will be necessary.
References
[1] National Center for Health Statistics. (2021). Migraine prevalence in the United States.
[2] FDA. (2019). Approval of Nerivio for acute migraine treatment.
[3] MarketResearch.com. (2022). Neuromodulation Devices Market Report.
[4] IQVIA. (2022). U.S. pharmaceutical and device reimbursement landscape.
[5] GlobalData. (2023). Migraine management market dynamics and forecasts.
